从医药分开到医保结算 京津冀吉辽晒医改好经验

2018-12-23 苏浩(整理) 健康界

12月22日,国家卫生健康委员会在北京召开新闻发布会。会上,北京市卫生健康委主任雷海潮、北京市西城区政府副区长郁治、天津市蓟州区政府副区长王俊茹、河北省黄骅市政府市长宋忠秋、辽宁省辽阳市政府副市长原阳、吉林省白城市政府副市长梁仰椿分别介绍各地有关深化医改工作的典型经验。北京医药分开综合改革成效显着“2017年3月,北京市政府印发《医药分开综合改革实施方案》,改革实施以来,迈出坚实步伐,发生积极

12月22日,国家卫生健康委员会在北京召开新闻发布会。会上,北京市卫生健康委主任雷海潮、北京市西城区政府副区长郁治、天津市蓟州区政府副区长王俊茹、河北省黄骅市政府市长宋忠秋、辽宁省辽阳市政府副市长原阳、吉林省白城市政府副市长梁仰椿分别介绍各地有关深化医改工作的典型经验。

北京医药分开综合改革成效显着

“2017年3月,北京市政府印发《医药分开综合改革实施方案》,改革实施以来,迈出坚实步伐,发生积极变化,总体平稳有序,各方反响良好,截至2018年11月底,已完成门急诊量3.5亿人次,580万出院和住院病人治疗有序。”北京市卫生健康委主任雷海潮介绍。

据了解,北京市目前已建成58个综合医联体,16个区全覆盖;建立8个专业、28个专科医联体,涵盖医院近200所。建立34个紧密型医联体,不断完善内部治理机制。2018年1—10月,医联体内双向转诊患者共计15.3万人次,比去年同期增加8.8%。

在药品采购方面,北京市稳步实施药品阳光采购,医药费用增幅下降明显。改革以来全市医药费用仅增长6%,为2000年以来费用增幅的最低期。药品阳光采购金额累计1066亿元,节省药品费用超101亿元,仅药品阳光采购一项措施就使得药价整体下降8.6%。

除此之外,北京市持续改善医疗服务,公众和患者皆给予较高评价。改进预约就诊服务,三级医院预约就诊已占到近70%,部分医院达到90%,预约就诊时间精准到1小时甚至半小时以内,患者门诊和大型检查的等候时间减少。

国家统计局北京调查总队在二三级医院对患者开展的独立调查显示,91.7%的患者支持医药分开综合改革,82.2%的患者认为改革政策有利于分级诊疗,83.8%的患者对医疗收费持肯定态度,90%以上的患者满意就医状况。

北京市西城区 推进“三纵两横一平台”紧密型医联体建设

北京市西城区政府副区长郁治介绍称,自2016年以来,西城区结合实际,提出构建“三纵两横一平台”的紧密型医联体建设思路,促进分级诊疗机制有效形成。

“三纵两横一平台”,即推进社区卫生服务中心与区属医院管理一体化、基本医疗一体化,与公共卫生机构公共卫生一体化等三个纵向一体化发展;促进区属医疗卫生机构与高等院校和驻区三级医院、社会资本办医机构两个横向协同发展;打造一个区域卫生信息化平台,促进分级诊疗机制有效形成。

据介绍,为深化家庭医生签约服务,西城区建立了15分钟可及的社区卫生服务圈,每万名居民拥有的全科医生数量达3.2人。西城区率先建设154个以优秀全科医生命名的家庭医生工作室,为患者提供连续性健康管理

经过三年探索,西城区医联体建设初见成效,2017年西城区社区卫生服务机构总诊疗人次为365.13万人次,比2016年增长22.31%,较2010年增长100.61%。区属医院总诊疗人次呈下降趋势,2017年为404.5955万人次,比2016年降低24.85%。

郁治表示,下一步西城区将会进一步完善工作机制,深化家庭医生签约服务,逐步建立社区首诊、双向转诊、急慢分治、上下联动的分级诊疗模式。

天津市蓟州区 破除“以药养医” 深化公立医院综合改革

天津市蓟州区政府副区长王俊茹在发布会上表示,自2015年12月1日起,蓟州区全面启动了区人民医院、区中医院两所公立医院改革。在实施改革过程中,蓟州区本着“保基本、强基层、建机制”的基本原则,坚持医疗、医保、医药“三医联动”,破除“以药养医”,城乡一体、三级联动、“小病不出村、常见病不出镇、大病不出区”的医疗服务格局初步形成,改革成效初步显现。

“三抓”坚持政府办医。一是抓推动,统筹谋划实施。着力构建“大卫生”“大健康”工作格局。二是抓投入,落实经费保障。将退休人员基本养老金以外的物价、取暖等四项补贴和在职人员养老保险补助纳入区财政预算。三是抓硬件,改善医疗环境。

该区加强药品耗材采购和使用监控,对高值耗材实行京津冀联合挂网采购,价格降幅达40%以上,切实减轻群众就医负担。

河北省黄骅市 “四赋”推动基层健康管理

“自2017年以来,黄骅市认真贯彻党的十九大精神和“健康中国”战略,深入推进基层医药卫生体制改革,围绕推动基层健康管理,赋予家庭医生管医保的权力,让家庭医生承担‘管健康’和‘管医保’双重角色,既强化了家庭医生服务基层群众的责任与权力,又促进了医保费用的合理使用,取得了初步成效。” 河北省黄骅市政府市长宋忠秋介绍称。

其中,该市从以下四个方面,推动基层健康管理。一是赋能,建立健康大数据管理平台,评估居民健康状况。同时,提升家庭医生的素质能力,全市已有150多名家庭医生,通过健康管理师的资格认定。

二是赋责,强化家庭医生的激励考核。明确主动预防职责,为每一个签约居民定制个性化健康干预方案。提升居民参与感和获得感,完善家庭医生考核机制,提升家庭医生社会地位。

三是赋权,明确家庭医生的职责权利。通过政府政策引导,居民通过家庭医生开展健康管理和就医引导,将获得政府为其投保的意外险,发生重大心脑血管疾病的获得5000元补偿。推行全程跟踪服务,家庭医生全程参与医疗机构诊疗过程和大额治疗方案。赋予家庭医生医保控费权利,对签约居民在二级以上医疗机构的诊疗行为进行全程监督。

四是赋利,调动家庭医生的积极性。市政府从医保定点商业保险公司拿出专项资金150万元,为家庭医生开展基层健康管理的奖励绩效。

辽宁省辽阳市 精准医疗扶贫兜底线 脱贫攻坚惠民生

辽宁省辽阳市政府副市长原阳介绍了该市精准医疗扶贫的工作成效。从2016年开展精准医疗扶贫工作以来,共收治精准医疗扶贫患者30438人次,共发生医疗总费用约2.1亿元,在政策性报销之外,精准医疗扶贫专项基金支出4455万元,定点医院兜底约3351万元。

为解决“钱”从哪里来的问题,在保障新农合基金平稳规范运行的基础上,辽阳市设立“新农合精准健康扶贫专项基金”,全力保障精准医疗扶贫。

2016年至2018年,辽阳市从新农合历年节余的资金中提取5000万元,用于建档立卡贫困患者政策补偿之外的救助,不足部分由定点医疗机构兜底,对建档立卡未脱贫患者实行定点医院住院免费治疗政策,对已脱贫患者实行定点医院住院新农合倾斜性补偿政策,确保贫困患者治病零负担或低负担。

精准医疗扶贫开展以来,辽阳市先后多次组织精准医疗扶贫定点医院进村入户,开展全面筛查,确定建档立卡贫困家庭患者1.7万人,根据核查情况实行分级分类救治。目前该市共为居家治疗慢病患者免费投药2.1万人次、价值200万元。

吉林省白城市 数据“领跑”群众“零跑”

吉林省白城市社会医疗保险管理局以便民、提效、高质为出发点,安排部署了“只跑一次”改革。率先建设“白城医保”微信公众服务平台,实现全市医保个人账户、医保待遇等所有查询业务网上查询。其中,89项医保经办业务100%实现“只跑一次”办结,其中35项业务实现“零跑腿”办结,54项业务“只跑一次”办结。

吉林省白城市政府副市长梁仰椿介绍,为确保微信服务平台运行更顺利,白城市还完善了四项保障措施:一是建立网络平台补充体系,向参保人推送业务提醒信息,对微信平台形成有效补充和宣传。二是建立电子档案管理系统,对所有参保人员信息建立完备数据库,实行档案数字化管理。三是构建信息安全屏障,将所有信息化设备托管至联通公司的云计算中心,实现“人脸识别”身份认证。四是权利优化线上线下服务机制,构建事前咨询“一口清”、网上办理“一键通”、窗口服务“一次成”、系统协同“一体系”的“四个一”工作机制,全面推行全程代办。

据统计,截至目前,每天通过“白城医保”微信公众服务平台共办理医保业务占每天业务总量的39%,在线办理个人缴费业务22万多笔,达2700多万元,单位业务3万多笔,定点医疗机构结算业务5100多笔,跨省异地就医结算备案1800余人次,省内转诊转院1.4万人次,省外转诊近***次,成效明显。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670267, encodeId=b73816e0267f5, content=<a href='/topic/show?id=c50be87281c' target=_blank style='color:#2F92EE;'>#结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78728, encryptionId=c50be87281c, topicName=结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178c26602075, createdName=vividelife, createdTime=Sat Jun 08 06:01:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659907, encodeId=9b6b165990e7e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Sat Dec 29 16:01:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006109, encodeId=b957200610984, content=<a href='/topic/show?id=269f3388e6a' target=_blank style='color:#2F92EE;'>#医保结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33887, encryptionId=269f3388e6a, topicName=医保结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Jul 17 03:01:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287062, encodeId=e6a9128e06289, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409757, encodeId=d3b61409e577a, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534919, encodeId=1ea51534919cc, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
    2019-06-08 vividelife
  2. [GetPortalCommentsPageByObjectIdResponse(id=1670267, encodeId=b73816e0267f5, content=<a href='/topic/show?id=c50be87281c' target=_blank style='color:#2F92EE;'>#结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78728, encryptionId=c50be87281c, topicName=结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178c26602075, createdName=vividelife, createdTime=Sat Jun 08 06:01:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659907, encodeId=9b6b165990e7e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Sat Dec 29 16:01:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006109, encodeId=b957200610984, content=<a href='/topic/show?id=269f3388e6a' target=_blank style='color:#2F92EE;'>#医保结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33887, encryptionId=269f3388e6a, topicName=医保结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Jul 17 03:01:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287062, encodeId=e6a9128e06289, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409757, encodeId=d3b61409e577a, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534919, encodeId=1ea51534919cc, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1670267, encodeId=b73816e0267f5, content=<a href='/topic/show?id=c50be87281c' target=_blank style='color:#2F92EE;'>#结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78728, encryptionId=c50be87281c, topicName=结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178c26602075, createdName=vividelife, createdTime=Sat Jun 08 06:01:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659907, encodeId=9b6b165990e7e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Sat Dec 29 16:01:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006109, encodeId=b957200610984, content=<a href='/topic/show?id=269f3388e6a' target=_blank style='color:#2F92EE;'>#医保结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33887, encryptionId=269f3388e6a, topicName=医保结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Jul 17 03:01:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287062, encodeId=e6a9128e06289, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409757, encodeId=d3b61409e577a, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534919, encodeId=1ea51534919cc, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1670267, encodeId=b73816e0267f5, content=<a href='/topic/show?id=c50be87281c' target=_blank style='color:#2F92EE;'>#结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78728, encryptionId=c50be87281c, topicName=结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178c26602075, createdName=vividelife, createdTime=Sat Jun 08 06:01:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659907, encodeId=9b6b165990e7e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Sat Dec 29 16:01:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006109, encodeId=b957200610984, content=<a href='/topic/show?id=269f3388e6a' target=_blank style='color:#2F92EE;'>#医保结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33887, encryptionId=269f3388e6a, topicName=医保结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Jul 17 03:01:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287062, encodeId=e6a9128e06289, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409757, encodeId=d3b61409e577a, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534919, encodeId=1ea51534919cc, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
    2018-12-25 tidiq
  5. [GetPortalCommentsPageByObjectIdResponse(id=1670267, encodeId=b73816e0267f5, content=<a href='/topic/show?id=c50be87281c' target=_blank style='color:#2F92EE;'>#结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78728, encryptionId=c50be87281c, topicName=结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178c26602075, createdName=vividelife, createdTime=Sat Jun 08 06:01:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659907, encodeId=9b6b165990e7e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Sat Dec 29 16:01:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006109, encodeId=b957200610984, content=<a href='/topic/show?id=269f3388e6a' target=_blank style='color:#2F92EE;'>#医保结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33887, encryptionId=269f3388e6a, topicName=医保结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Jul 17 03:01:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287062, encodeId=e6a9128e06289, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409757, encodeId=d3b61409e577a, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534919, encodeId=1ea51534919cc, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]
    2018-12-25 cathymary
  6. [GetPortalCommentsPageByObjectIdResponse(id=1670267, encodeId=b73816e0267f5, content=<a href='/topic/show?id=c50be87281c' target=_blank style='color:#2F92EE;'>#结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78728, encryptionId=c50be87281c, topicName=结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178c26602075, createdName=vividelife, createdTime=Sat Jun 08 06:01:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659907, encodeId=9b6b165990e7e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Sat Dec 29 16:01:00 CST 2018, time=2018-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006109, encodeId=b957200610984, content=<a href='/topic/show?id=269f3388e6a' target=_blank style='color:#2F92EE;'>#医保结算#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33887, encryptionId=269f3388e6a, topicName=医保结算)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Wed Jul 17 03:01:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287062, encodeId=e6a9128e06289, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409757, encodeId=d3b61409e577a, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534919, encodeId=1ea51534919cc, content=<a href='/topic/show?id=10123528e63' target=_blank style='color:#2F92EE;'>#医药分开#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35287, encryptionId=10123528e63, topicName=医药分开)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=202612558221, createdName=zhishijing, createdTime=Tue Dec 25 04:01:00 CST 2018, time=2018-12-25, status=1, ipAttribution=)]

相关资讯

处方外流正式落地!医院内外药品同规同价

广东省第二人民医院率先开通处方流转平台服务。

致命禁令 杀死药房托管还差几步?

药房托管,必将失败” 类似这样的“判词”,在药房托管狂潮涌起的近些年里,可谓是不绝于耳。医药圈内谈起药房托管,无不是一副“双手抱胸、眉头紧皱”的严肃态度。甚至有业内人士如此评论道:“从动机、过程、机制最后到效果,药房托管无任何正面意义可谈!”。

聊聊“医药分开”那些事儿

自2009年以来,“医药分开”一直是医改的核心内容之一。近年来,为了探索“医药分开”的有效途径,各地陆续推出了“药房托管”、门诊药房剥离、取消门诊药房等改革探索。然而,“医药分开”推行了二十余年,始终不及预期。

处方外流市场规范化 易复诊全面落地医药分开

在医药分开、不限制处方外流等政策推动下,外流处方市场不断增长,渐成大势所趋。据米内网数据显示,2018年中国药品市场规模将增至1.76万亿元,受政策因素影响,处方外流的市场规模将突破1300亿元。华创证券的研报认为,如处方院外销售额占处方销售总额的45%,院外处方将新增3000亿元,这一增量将主要由零售药店、第三终端等承接。这也带来了处方院外化市场的快速生长,药企、药店、流通企业、互联网公司

“医”和“药”是不是一定得分开?

说到“医药分开”这个词,它到底是什么,其实在概念上从来没有界定。

京津冀地区:剑指控费 一砍再砍!降价15% 每年节省8亿元!

京津冀医用耗材联合采购来了,跟吗?